Gilead tackles a big PhIII program for blockbuster hopeful filgotinib
Gilead $GILD has embarked on an ambitious Phase III program for filgotinib, one of the most closely-watched drugs now in the late-stage pipeline for rheumatoid arthritis.
The storied Galapagos drug, which had been dumped by AbbVie only to be quickly picked back up in a rich deal with Gilead, is being put through three late-stage studies – dubbed FINCH 1, 2 and 3 – which will test two doses in more than 3,000 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.